治疗后早期(第1-4天)血清hCG水平变化可预测输卵管异位妊娠单剂量甲氨蝶呤治疗成功
本研究为前瞻性队列研究,纳入322例输卵管异位妊娠(初始hCG≥1000且≤5000 IU/l)接受单剂量甲氨蝶呤治疗的女性,评估第1-4天血清hCG变化对治疗成功的预测价值。总体治疗成功率为59%(189/322)。第1-4天hCG任何下降预测成功的敏感度为58%、特异度为84%,阳性预测值85%、阴性预测值57%。
要点
- 第1-4天hCG任何下降预测单剂量甲氨蝶呤治疗成功的阳性预测值为85%。
- 第1-4天hCG上升<18%为最佳阈值,预测成功的敏感度79%、特异度74%。
- 作者建议对第1-4天hCG下降或仅轻度上升(<18%)者提供早期 reassurance。
核心结论
- 在初始hCG≥1000且≤5000 IU/l的输卵管异位妊娠女性中,第1-4天血清hCG任何下降预示单剂量甲氨蝶呤治疗成功可能性为85%(95% CI 76.8-90.6)。
- 作者建议临床医生对第1-4天血清hCG下降或仅轻度上升(<18%)的女性提供早期 reassurance,告知治疗可能有效。
研究设计与样本
- 前瞻性队列研究,数据来源于英国多中心随机对照试验GEM3(甲氨蝶呤联合吉非替尼 vs 甲氨蝶呤联合安慰剂),本分析纳入两个治疗组。
- 共322例输卵管异位妊娠女性,初始hCG≥1000且≤5000 IU/l,接受单剂量甲氨蝶呤治疗。
主要发现
- 总体单剂量甲氨蝶呤治疗成功率为59%(n=189/322)。
- 第1-4天血清hCG任何下降的似然比>3;第1-7天血清hCG下降>20%的似然比达5。
- 第1-7天和第4-7天血清hCG任何上升均强烈降低成功机会。
- 第1-4天hCG任何下降预测成功的敏感度58%、特异度84%,阳性预测值85%、阴性预测值57%。
- 第1-4天hCG上升<18%为最佳阈值,预测成功的敏感度79%、特异度74%,阳性预测值82%、阴性预测值69%。
关键数值与推荐
- 治疗成功定义为单剂量甲氨蝶呤治疗后输卵管异位妊娠完全且无事件地消退至血清hCG<30 IU/l,无需额外治疗。
- 第1-4天hCG任何下降:敏感度58%、特异度84%、阳性预测值85%、阴性预测值57%。
- 第1-4天hCG上升<18%:敏感度79%、特异度74%、阳性预测值82%、阴性预测值69%。
临床怎么用
- 作者建议对第1-4天血清hCG下降或仅轻度上升(<18%)的女性提供早期 reassurance,告知治疗可能有效。
- 当前指南主张若第4-7天hCG下降未超过15%则进行干预。
局限性
- 研究结果可能受干预偏倚限制,该偏倚源于现有指南影响对依赖第7天血清hCG水平的hCG变化的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the capacity of the change between Day 1 and Day 4 post-treatment serum human chorionic gonadotropin (hCG) levels for predicting single-dose methotrexate treatment success in tubal ectopic pregnancy? SUMMARY ANSWER: Any fall in Days 1-4 serum hCG signified an 85% (95% CI 76.8-90.6) likelihood of treatment success for women with tubal ectopic pregnancy (initial hCG of ≥1000 and ≤5000 IU/l) managed with single-dose methotrexate. WHAT IS KNOWN ALREADY: For those with tubal ectopic pregnancy managed by single-dose methotrexate, current guidelines advocate intervention if Days 4-7 hCG fails to fall by >15%. The trajectory of hCG over Days 1-4 has been proposed as an early indicator that predicts treatment success, allowing early reassurance for women. However, almost all prior studies of Days 1-4 hCG changes have been retrospective. STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study of women with tubal ectopic pregnancy (pre-treatment hCG of ≥1000 and ≤5000 IU/l) managed with single-dose methotrexate. The data were derived from a UK multicentre randomized controlled trial of methotrexate and gefitinib versus methotrexate and placebo for treatment of tubal ectopic pregnancy (GEM3). For this analysis, we include data from both treatment arms. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants were categorized according to single-dose methotrexate treatment success or failure. Treatment success for this analysis was defined as complete and uneventful resolution of tubal ectopic pregnancy to serum hCG <30 IU/l following single-dose methotrexate treatment without additional treatment. Patient characteristics of the treatment success and failure groups were compared. Changes in Days 1-4, 1-7, and 4-7 serum hCG were evaluated as predictors of treatment success through receiver operating characteristic curve analysis. Test performance characteristics were calculated for percentage change ranges and thresholds including optimal classification thresholds. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 322 women with tubal ectopic pregnancy were treated with single-dose methotrexate. The overall single-dose methotrexate treatment success rate was 59% (n = 189/322). For any fall in serum hCG on Days 1-4, likelihood ratios were >3, while for any fall of serum hCG >20% on Days 1-7, likelihood ratios reached 5. Any rise of serum hCG on Days 1-7 and 4-7 strongly reduced the chance of success. Any fall in Days 1-4 hCG predicted single-dose methotrexate treatment success with a sensitivity of 58% and specificity 84%, resulting in positive and negative predictive values of 85% and 57%, respectively. Any rise in Days 1-4 serum hCG <18% was identified as an optimal test threshold that predicted treatment success with 79% sensitivity and 74% specificity, resulting in 82% positive predictive value and 69% negative predictive value. LIMITATIONS, REASONS FOR CAUTION: Our findings may be limited by intervention bias resulting from existing guidelines which influences evaluation of hCG changes reliant on Day 7 serum hCG levels. WIDER IMPLICATIONS OF THE FINDINGS: Examining a large prospective cohort, we show the value of Days 1-4 serum hCG changes in predicting single-dose methotrexate treatment success in tubal ectopic pregnancy. We recommend that clinicians provide early reassurance to women who have a fall or only a modest (<18%) rise in Days 1-4 serum hCG levels, that their treatment will likely be effective. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by funding from the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership (grant reference number 14/150/03). A.W.H. has received honoraria for consultancy for Ferring, Roche, Nordic Pharma and AbbVie. W.C.D. has received honoraria from Merck and Guerbet and research funding from Galvani Biosciences. L.H.R.W. has received research funding from Roche Diagnostics. B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). B.W.M. also reports consultancy for ObsEva and Merck and travel support from Merck. The other authors declare no competing interests. TRIAL REGISTRATION NUMBER: This study is a secondary analysis of the GEM3 trial (ISRCTN Registry ISRCTN67795930).
引用
- Mackenzie SC, Moakes CA, Doust AM, et al. Early (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy. Hum Reprod. 2023. PMID: 37178269. doi:10.1093/humrep/dead089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。